查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1931185

全球血脂檢測套組市場（按產品類型、檢測類型、技術、最終用戶和分銷管道分類）預測（2026-2032年）

Blood Lipid Test Kits Market by Product Type, Test Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血脂檢測套組市場價值將達到 6.7146 億美元，到 2026 年將成長至 7.065 億美元，到 2032 年將達到 10.2708 億美元，複合年成長率為 6.25%。

關鍵市場統計數據
基準年 2025 6.7146億美元
預計年份：2026年 7.065億美元
預測年份 2032 1,027,080,000 美元
複合年成長率 (%) 6.25%

關於不斷變化的臨床、技術和操作方面的考慮因素的背景介紹，這些因素正在重新定義臨床路徑中的脂質檢測。

血脂檢測領域橫跨臨床診療、消費者健康和科研三大領域，既需要嚴謹的技術，也需要切實可行的應用模式。檢測化學、小型化分析儀和數位化監測技術的進步，拓展了血脂指標的檢測範圍和方式，使臨床醫生和患者能夠從間歇性檢測轉向更連續、更具情境性的評估。同時，監管、報銷考量和工作流程整合要求等因素，仍在影響哪些技術能夠廣泛應用。

脂質檢測領域的變革性診斷融合了照護現場技術、試劑革新、數位整合和供應鏈敏捷性。

診斷領域的最新變革正在重塑脂質檢測的開發、檢驗和應用方式。照護現場分析儀的創新將檢查室級的功能整合到緊湊的桌上型和攜帶式設備中，使臨床上可接受的脂質檢測能夠在患者附近進行。同時，試劑研發也更加重視長期保存期限、簡化工作流程以及與自動化檢查室的兼容性，從而降低了傳統集中式和分散式檢查模式之間的壁壘。

評估美國關稅調整對診斷產品採購、製造和分銷動態的多方面營運和供應鏈影響

美國政策變化和關稅制度調整正對整個診斷價值鏈產生實際影響，波及採購決策、供應商關係和庫存管理實務。關稅變化影響進口儀器零件、特殊試劑和耗材，迫使採購部門重新評估其供應商多元化策略和總到岸成本。為此，一些製造商和經銷商正在重新評估其生產基地、供應商合約和庫存緩衝，以降低進口成本波動帶來的風險。

將推動市場採用的因素與產品類型、檢測方式、終端用戶需求、試劑化學性質、分銷管道和脂質分析物優先級聯繫起來的可操作的細分洞察

精細化的細分框架能夠提供切實可行的洞察，幫助我們了解不同產品、測試形式、最終用戶、技術和分銷模式的採用路徑和效能預期。就產品類型而言，設備包括用於中心檢查室的桌上型分析儀和照護現場檢測的即時分析儀；而試劑和耗材則分為試劑盒和試紙條，必須符合分析儀的兼容性和工作流程要求。這種差異化決定了產品開發的重點：設備製造商專注於通量、準確性和符合人體工學的設計，而試劑供應商則強調穩定性、批間一致性和簡化的通訊協定。

各區域（美洲、歐洲、中東和非洲、亞太地區）的診斷應用模式和商業化需求將指南我們的區域市場策略。

區域趨勢將對應用模式和商業化策略產生重要影響。在美洲，對整合式醫療路徑的重視、強大的臨床實驗室網路以及消費者對居家監測日益成長的需求，都推動了對桌上型分析儀和先進的照護現場的興趣。私人和公共支付方的結構會影響採購行為，而監管路徑和報銷政策則決定了新型設備進入臨床實踐的速度。

透過平台多功能性、供應彈性和數位化整合，制定競爭和合作策略，使製造商、試劑供應商和通路合作夥伴脫穎而出。

在血脂檢測領域，競爭優勢取決於技術差異化、試劑生態系統、服務和支援能力以及策略聯盟的綜合作用。主要企業正致力於提昇平台的多功能性，使儀器能夠執行多種檢測，從而提高其在臨床工作流程中的效用。同時，那些能夠確保試劑供應鏈穩定並提供完善品管系統的製造商，正在為高通量檢查室和分散式醫療機構創造永續的價值提案。

製造商和相關人員可採取的切實可行的策略重點，以加強其平台、保障其供應鏈、加速數位整合並改善客戶體驗。

為了將市場動態轉化為永續優勢，產業領導者應優先考慮以下關鍵舉措：首先，透過投資平台模組化，簡化終端用戶的採購流程，該平台應同時支援高通量桌上型分析儀和攜帶式照護現場設備，並確保不同產品系列之間的試劑相容性。這將降低檢查室的准入門檻，並支援在醫療機構中大規模部署。

本研究採用全面且經過驗證的檢驗調查方法，結合關鍵相關人員訪談、二手文獻回顧和供應鏈壓力測試，以得出可靠的研究結果。

本摘要的研究途徑融合了定性和定量資料收集，並採用嚴格的檢驗程序，以確保研究結果具有可操作性和實證性。主要資料來源包括對臨床實驗室主任、採購人員、臨床終端使用者和診斷行業高管進行結構化訪談，以收集有關性能、工作流程和採購方面的實際考慮。此外，還對供應商進行了訪談，以了解生產限制、試劑穩定性改進和分銷策略。

摘要強調了以下共識：診斷品質、可近性、互通性和供應鏈韌性是未來應用的關鍵促進因素。

本次調查的綜合結果表明，血脂檢測正經歷著一場由技術創新、數位整合和醫療模式變革所驅動的變革。儘管診斷的準確性和可靠性仍然至關重要，但施行地點、檢測結果如何融入醫療流程以及如何維持穩定的供應鏈供應，這些因素正日益成為定義其價值的關鍵所在。隨著相關人員不斷調整，集中式檢查室的準確性與分散式檢測的可及性之間的平衡將決定臨床實踐中最終採用的解決方案。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的血脂檢測套組市場

  • 裝置
  • 試劑和耗材
    • 成套工具
    • 條

第9章 依檢測類型分類的血脂檢測套組市場

  • 自動分析儀
  • 即時檢測

第10章 依技術分類的血脂檢測套組市場

  • 幹化學
  • 液體試劑

第11章 以最終用戶分類的血脂檢測套組市場

  • 臨床檢查室
  • 居家醫療環境
  • 醫院和診所
  • 研究所

第12章 血脂檢測套組市場（依通路分類）

  • 離線
  • 線上

第13章 血脂檢測套組市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血脂檢測套組市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國血脂檢測套組市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血脂檢測套組市場

第17章 中國血脂檢測套組市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alfresa Holdings Corporation
  • ARKRAY, Inc.
  • Asahi Kasei Corporation
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • Daiichi Sankyo Company, Limited
  • Denka Seiken Co., Ltd.
  • Eiken Chemical Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Fujifilm Wako Shibayagi Corporation
  • Horiba, Ltd.
  • Kyowa Medex Co., Ltd.
  • Mitsubishi Chemical Medience Corporation
  • Nitto Boseki Co., Ltd.
  • Ortho Clinical Diagnostics
  • Randox Laboratories Ltd.
  • Sekisui Medical Co., Ltd.
  • Shino-Test Corporation
  • Siemens Healthineers AG
  • SRL, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Toyobo Co., Ltd.
  • Wako Pure Chemical Industries, Ltd.
Product Code: MRR-7B550E008DA5

The Blood Lipid Test Kits Market was valued at USD 671.46 million in 2025 and is projected to grow to USD 706.50 million in 2026, with a CAGR of 6.25%, reaching USD 1,027.08 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 671.46 million
Estimated Year [2026] USD 706.50 million
Forecast Year [2032] USD 1,027.08 million
CAGR (%) 6.25%

Contextual introduction to the evolving clinical, technological, and operational considerations that are redefining blood lipid testing across care pathways

The landscape of blood lipid testing intersects clinical care, consumer health, and research in ways that demand both technical rigor and pragmatic delivery models. Advances in assay chemistry, miniaturized analyzers, and digital monitoring have expanded where and how lipid metrics are captured, enabling clinicians and patients to move beyond episodic testing toward more continuous and contextualized assessment. At the same time, regulatory scrutiny, reimbursement considerations, and workflow integration requirements continue to shape which technologies achieve widespread adoption.

This executive summary synthesizes the critical vectors influencing diagnostic performance, procurement decisions, and clinical utility. It foregrounds how device form factors, reagent stability, and interoperability with electronic health records converge with care delivery models to influence uptake. The narrative emphasizes practical implications for manufacturers, laboratory directors, procurement officers, and clinical leaders, highlighting operational levers that can accelerate adoption while maintaining analytical quality.

Throughout this document, the focus remains on translating technological and policy developments into decision-useful insights. The objective is to inform strategy and operational planning for stakeholders seeking to align product roadmaps, distribution strategies, and clinical partnerships with evolving diagnostic requirements and user expectations.

Transformative forces in diagnostics driving convergence of point-of-care technology, reagent evolution, digital integration, and supply chain agility in lipid testing

Recent shifts within diagnostics are reframing how lipid tests are developed, validated, and deployed across multiple settings. Innovations in point-of-care analyzers have compressed laboratory capabilities into compact benchtop and handheld devices, allowing clinically acceptable lipid measurements to be obtained closer to patients. Concurrently, reagent development has emphasized longer shelf life, simplified workflows, and compatibility with automated platforms, reducing the friction that historically separated central laboratories from decentralized testing models.

Digital capabilities have further accelerated transformation by enabling remote result delivery, longitudinal trend visualization, and integration with care management platforms. These capabilities facilitate clinician oversight while empowering patients to engage with their lipid profiles more proactively. In addition, the convergence of wearable sensors and connected handheld devices supports earlier detection of metabolic risk and better adherence monitoring, prompting new clinical pathways that emphasize prevention and chronic disease management.

Supply chain optimization and manufacturing modularity are also reshaping vendor strategies. Producers are prioritizing platform flexibility and reagent standardization to serve both high-throughput laboratories and point-of-care environments. As a result, stakeholders must balance innovation with regulatory, quality, and interoperability demands to successfully navigate the transition toward more distributed, digitally enabled lipid testing ecosystems.

Evaluating the multifaceted operational and supply chain ramifications of United States tariff adjustments on diagnostic procurement, manufacturing, and distribution dynamics

Policy changes and adjustments to tariff regimes in the United States introduce tangible effects along the diagnostic value chain, influencing procurement decisions, supplier relationships, and inventory management practices. Tariff changes affect imported instrumentation components, specialized reagents, and consumables, prompting purchasing teams to reassess supplier diversification strategies and total landed costs. In response, some manufacturers and distributors are reevaluating production locations, supplier contracts, and inventory buffers to mitigate exposure to import cost volatility.

The immediate operational implications include longer lead times for certain imported components and selective reallocation of sourcing toward domestic or tariff-exempt suppliers where feasible. These adjustments create both short-term logistical complexity and longer-term strategic opportunities for local manufacturing partnerships and regional supply hubs. Procurement functions are increasingly incorporating scenario planning and supplier scorecards that capture tariff risk, supplier resilience, and contingency capacity.

Clinicians and laboratory managers may encounter pricing adjustments for specific consumables or bundled systems, which can influence ordering cadence and stocking policies. To preserve continuity of care and testing throughput, laboratories are prioritizing forecasting discipline and supplier engagement to ensure uninterrupted access to critical reagents and strips. Overall, tariff-driven shifts are amplifying the importance of supply chain transparency, flexible sourcing, and collaborative risk-sharing arrangements across the diagnostic ecosystem.

Actionable segmentation insights that link product categories, test modalities, end-user needs, reagent chemistries, distribution channels, and lipid analyte priorities to adoption drivers

A nuanced segmentation framework yields practical insights into adoption pathways and performance expectations across products, test formats, end users, technologies, and distribution models. When product type is considered, instruments encompass benchtop analyzers suited for central laboratories and point-of-care analyzers designed for near-patient testing, while reagents and consumables are differentiated into kits and strips that must align with analyzer compatibility and workflow requirements. This differentiation informs product development priorities, with instrument manufacturers focusing on throughput, accuracy, and ergonomics and reagent suppliers emphasizing stability, lot-to-lot consistency, and simplified protocols.

Examining test type reveals a bifurcation between automated analyzers that deliver high-throughput, standardized results and point-of-care testing modalities that include handheld devices and emerging wearable sensors. The trade-offs between convenience and analytical performance shape clinical adoption, with automated platforms favored where diagnostic precision and volume are paramount and point-of-care tools prioritized in settings that value rapid decision-making and decentralized access. End user dynamics further influence product requirements: clinical laboratories demand integration, calibration protocols, and serviceability; home care settings emphasize ease of use and remote connectivity; hospitals and clinics require interoperability with health IT systems; and research institutes focus on analytical flexibility and data granularity.

Technology choices between dry chemistry and liquid reagents have implications for storage, shelf life, and calibration regimes, affecting both operational workflows and user training. Distribution channels-direct sales, distributors, and online retail-each present unique commercialization pathways that influence pricing strategy, after-sales service expectations, and regulatory compliance responsibilities. Finally, lipid type segmentation across high-density lipoprotein, low-density lipoprotein, total cholesterol, and triglycerides has clinical significance that dictates assay design, validation needs, and reporting formats to meet the diagnostic and therapeutic decision points used by clinicians.

Regional diagnostic adoption patterns and commercialization imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform tailored market approaches

Regional dynamics shape adoption models and commercialization strategies in meaningful ways. In the Americas, emphasis on integrated care pathways, strong clinical laboratory networks, and increasing consumer demand for home monitoring have catalyzed interest in both benchtop analyzers and advanced point-of-care solutions. Private and public payor structures influence procurement behaviors, while regulatory pathways and reimbursement policy determine the speed at which new device classes can scale within clinical practice.

In Europe, the Middle East & Africa, clinical and regulatory diversity creates a landscape where centralized laboratory infrastructure remains pivotal in many markets, but pockets of rapid point-of-care adoption are emerging in community health settings and private clinics. Supply chain constraints and local manufacturing priorities in some jurisdictions necessitate flexible commercial models and tailored service offerings. Interoperability with regional health information systems and alignment with public health screening initiatives are critical levers for broader adoption.

Asia-Pacific exhibits heterogenous adoption patterns driven by rapid urbanization, growing investment in primary care, and significant interest in consumer-facing diagnostics. High-density population centers create attractive volumes for scalable point-of-care deployments, while certain markets prioritize local manufacturing and cost control. Across regions, distribution strategies must be adapted to local procurement practices, regulatory expectations, and clinician preferences to ensure successful market entry and sustained uptake.

Competitive and partnership strategies that differentiate manufacturers, reagent suppliers, and channel partners through platform versatility, supply resilience, and digital integration

Competitive positioning in the blood lipid testing space is defined by a mix of technological differentiation, reagent ecosystems, service and support capabilities, and strategic partnerships. Leading companies are investing in platform versatility that allows instruments to process multiple analytes, thereby increasing utility across clinical workflows. At the same time, manufacturers that secure stable reagent supply chains and provide robust quality management systems create durable value propositions for high-volume laboratories and decentralized care sites.

Strategic partnerships between device manufacturers, reagent producers, and distribution networks are increasingly common, enabling bundled solutions that simplify procurement and technical support. Companies that offer digital integration tools-such as secure result transmission, data analytics, and EHR interoperability-gain an edge by reducing clinician burden and improving longitudinal patient management. Service models that combine preventive maintenance, rapid parts replacement, and remote troubleshooting reduce downtime and enhance customer loyalty.

New entrants and niche innovators are focusing on wearable sensors and consumer-oriented products, creating complementary value alongside established clinical platforms. These entrants often pursue collaborations with research institutions and healthcare systems to validate clinical utility and build clinician confidence. In aggregate, successful companies will be those that balance innovation with regulatory rigor, dependable supply chains, and after-sales excellence to meet diverse end-user requirements.

Practical strategic priorities for manufacturers and stakeholders to strengthen platforms, secure supply chains, accelerate digital integration, and enhance customer outcomes

Industry leaders should prioritize a set of targeted actions to convert market dynamics into sustainable advantages. First, invest in platform modularity that supports both high-throughput benchtop analyzers and portable point-of-care devices, while ensuring reagent compatibility across product families to simplify procurement for end users. This reduces friction for laboratory adoption and enables scalable rollouts across care settings.

Second, strengthen supply chain resilience by diversifying suppliers, establishing regional inventory hubs, and negotiating contingency agreements that mitigate the impact of tariff or logistics disruptions. Transparent supplier scorecards and scenario planning should be embedded in procurement and product launch processes. Third, accelerate digital integration by developing secure interoperability features that connect test results with electronic health records and patient management platforms, thereby increasing clinical workflow efficiency and enabling value-based care models.

Fourth, enhance customer support through outcome-focused service offerings that combine preventive maintenance, rapid response, and user training programs tailored to clinical and home settings. Fifth, pursue strategic collaborations with clinical networks, research institutions, and payors to generate real-world evidence that underscores clinical utility and supports reimbursement discussions. By aligning product design, commercial models, and operational resilience with user needs, industry leaders can accelerate adoption and create defensible differentiation.

Comprehensive and validated research methodology leveraging primary stakeholder interviews, secondary literature synthesis, and supply chain stress-testing for robust insights

The research approach underpinning this summary integrated qualitative and quantitative data collection with robust validation steps to ensure findings are actionable and evidence-based. Primary inputs included structured interviews with clinical laboratory directors, procurement leads, clinician end users, and diagnostic industry executives to capture practical considerations around performance, workflow, and procurement. These conversations were complemented by targeted supplier interviews to understand manufacturing constraints, reagent stability improvements, and distribution strategies.

Secondary sources comprised peer-reviewed literature on assay performance and clinical utility, regulatory guidance documents, and public policy analyses that inform reimbursement and procurement frameworks. Supply chain assessments evaluated component sourcing, logistics dependencies, and potential tariff exposures to identify operational risk points. Throughout the analysis, triangulation was used to reconcile differing perspectives and validate emergent themes, with particular attention to analytical accuracy, regulatory compliance, and real-world usability.

Where applicable, findings were stress-tested through scenario analysis focused on sourcing disruptions, reimbursement shifts, and rapid technology adoption. This layered methodology ensures that recommendations are grounded in practitioner experience and validated against documented evidence and supply chain realities.

Concluding synthesis highlighting the alignment of diagnostic quality, access, interoperability, and supply chain resilience as decisive factors for future adoption

Collectively, the insights synthesized here underscore that blood lipid testing is undergoing a period of purposeful evolution driven by technology, digital integration, and shifting care models. Diagnostic accuracy and reliability remain non-negotiable, yet value is increasingly defined by where and how tests are performed, how results are integrated into care pathways, and how supply chains sustain availability. As stakeholders adapt, a balance between centralized laboratory precision and decentralized accessibility will determine which solutions achieve clinical traction.

Organizations that invest in platform interoperability, reagent stability, and resilient sourcing will be better positioned to respond to clinician needs and procurement dynamics. Simultaneously, clear evidence of clinical utility and cost-effectiveness will facilitate conversations with payors and procurement authorities, supporting broader adoption. Leadership in this space will require not only technological excellence but also disciplined execution across commercialization, regulatory engagement, and post-market support.

Ultimately, the trajectory of blood lipid testing will favor solutions that make high-quality diagnostics more accessible across care settings while preserving analytical integrity. Stakeholders that align product design, service models, and strategic partnerships to those priorities stand to deliver measurable improvements in preventive care and chronic disease management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Lipid Test Kits Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Consumables
    • 8.2.1. Kits
    • 8.2.2. Strips

9. Blood Lipid Test Kits Market, by Test Type

  • 9.1. Automated Analyzers
  • 9.2. Point Of Care Testing

10. Blood Lipid Test Kits Market, by Technology

  • 10.1. Dry Chemistry
  • 10.2. Liquid Reagents

11. Blood Lipid Test Kits Market, by End User

  • 11.1. Clinical Laboratories
  • 11.2. Home Care Settings
  • 11.3. Hospitals And Clinics
  • 11.4. Research Institutes

12. Blood Lipid Test Kits Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Blood Lipid Test Kits Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Lipid Test Kits Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Lipid Test Kits Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Blood Lipid Test Kits Market

17. China Blood Lipid Test Kits Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Alfresa Holdings Corporation
  • 18.7. ARKRAY, Inc.
  • 18.8. Asahi Kasei Corporation
  • 18.9. Beckman Coulter, Inc.
  • 18.10. bioMerieux SA
  • 18.11. Daiichi Sankyo Company, Limited
  • 18.12. Denka Seiken Co., Ltd.
  • 18.13. Eiken Chemical Co., Ltd.
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. Fujifilm Wako Shibayagi Corporation
  • 18.16. Horiba, Ltd.
  • 18.17. Kyowa Medex Co., Ltd.
  • 18.18. Mitsubishi Chemical Medience Corporation
  • 18.19. Nitto Boseki Co., Ltd.
  • 18.20. Ortho Clinical Diagnostics
  • 18.21. Randox Laboratories Ltd.
  • 18.22. Sekisui Medical Co., Ltd.
  • 18.23. Shino-Test Corporation
  • 18.24. Siemens Healthineers AG
  • 18.25. SRL, Inc.
  • 18.26. Sysmex Corporation
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. Toyobo Co., Ltd.
  • 18.29. Wako Pure Chemical Industries, Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD LIPID TEST KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD LIPID TEST KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY AUTOMATED ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY AUTOMATED ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DRY CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DRY CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DRY CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY LIQUID REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY LIQUID REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY LIQUID REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 118. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 139. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 146. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)